Excepgen

RNA medicines with improved tolerability by dampening excessive innate immune responses

Built from URL

San Francisco

HealthcarePharmaceuticals & MedicineDeep TechBiotechDrug Discovery

Y CombinatorWinter 2019

AboutBuilt from URL

ExcepGen develops RNA-based therapeutics using their RNAx platform, which encodes proteins that alter cellular responses to RNA and lipid nanoparticles. Their technology focuses on dampening overactive innate immune responses to make RNA medicines more tolerable while maintaining efficacy.

ProblemBuilt from URL

See something off about this company?